IL-33 cleaved by elastase CELA1 promotes the development of HCC through the activation of ST2-positive Treg cells.224 DSF treatment markedly curtails the secretion of IL-1β and IL-33 and suppresses hepatic tumor formation, suggesting the potential of inhibitors targeting the pore-forming process of GSDMD in the treatment of HCC. The gene discussed is CELA1; the disease is hepatocellular carcinoma.